EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Trans-acting genetic modifiers of clinical severity in heterozygous β-Thalassemia trait

Joanna B Loh, Jules M Ross, Khaled M Musallam, Kevin H M Kuo

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-06007-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2024. Verfasst von Joanna B Loh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: beta-Thalassemia, Heterozygote, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 87 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a group of beta (β)-thalassemia trait 'carriers' (with heterozygous mutations) who should be asymptomatic with minor abnormalities in their hematological parameters, but experience more severe disease manifestations than predicted based solely on their β-globin genotype. This review focuses on literature describing trans-acting genetic modifiers outside of the α- and β-globin gene clusters that could cause this phenomenon. These genetic modifiers are categorized into: mutations affecting the quantity of alpha-globin products, non-globin mutations affecting erythropoiesis, membranopathies, enzymopathies and erythrocyte-independent modifiers of complications relating to β-thalassemia. Although some genetic determinants seem to correlate more directly with β-thalassemia trait severity, such as mutations in SUPT5H, PIEZO1 and hereditary elliptocytosis, the difficulties of linking the contribution of other modulating factors are elucidated in this review. Targeted next generation sequencing of hemolytic anemias can be helpful but also raises another quandary in interpreting variants of uncertain significance. The accrual of knowledge, along with the increased availability of genetic testing for genetic modifiers has considerable potential for clinical applications such as genetic counselling, decision-making for clinical interventions and prognostication, and perhaps generating new therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaHeterozygoteMutationHumansbeta-GlobinsSeverity of Illness IndexGenes, Modifieralpha-GlobinsIon Channels

Stichwörter der Autor:innen

AnemiaMutationsPhenotypeThalassemia

Substanzen

beta-GlobinsPIEZO1 protein, humanalpha-GlobinsIon Channels

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Center for Research on Rare Blood Disorders (CR-RBD), Burjeel Medical City, Abu Dhabi, United Arab Emirates.
  • Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
  • Division of Hematology, Department of Medicine, University of Toronto, Toronto, ON, Canada. kevin.kuo@uhn.ca.

Zitieren

APA

Loh, J. B., Ross, J. M., Musallam, K. M., & Kuo, K. H. M. (2024). Trans-acting genetic modifiers of clinical severity in heterozygous β-Thalassemia trait. Annals of Hematology. https://doi.org/10.1007/s00277-024-06007-0

Vancouver

Loh JB, Ross JM, Musallam KM, Kuo KHM. Trans-acting genetic modifiers of clinical severity in heterozygous β-Thalassemia trait. Annals of Hematology. 2024. doi:10.1007/s00277-024-06007-0

BibTeX
@article{Loh2024,
  author = {Loh, Joanna B and Ross, Jules M and Musallam, Khaled M and Kuo, Kevin H M},
  title = {Trans-acting genetic modifiers of clinical severity in heterozygous β-Thalassemia trait},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-06007-0}
}
Kostenlos starten →